On November 3, 2016 NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, reporteded several presentations at the upcoming 58th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) in San Diego, CA, December 3-6, 2016 (Press release, NantKwest, NOV 3, 2016, http://ir.nantkwest.com/phoenix.zhtml?c=254059&p=RssLanding&cat=news&id=2220144 [SID1234516468]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"As these presentations demonstrate, since our IPO in July 2016, NantKwest continues to make significant progress in our preclinical and clinical development efforts," said Patrick Soon-Shiong, MD, Chairman and CEO of NantKwest. "We are honored to present these results at the upcoming annual ASH (Free ASH Whitepaper) meeting and remain focused on bringing our novel, natural killer cell based therapies to the routine clinical cancer setting for a broad range of cancer types."
Presentation Summaries
Combination Therapy with Daratumumab and CAR-NK Targeting CS1 for Multiple Myeloma
Abstract #1342, View Source
Presenter: Yibo Zhang, PhD, Comprehensive Cancer Center, Ohio State University, Columbus, OH
Saturday, December 3, 2016, 5:30 – 7:30 PM, Hall GH
This poster will review the combination of Daratumumab and CS1.taNK therapy targeting two different tumor-associated antigens, both with potent efficacy in multiple myeloma, which may have synergistic effects.
Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-The-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia
Abstract #1649, View Source
Presenter: Michael Boyiadzis, MD, MHSc, University of Pittsburgh Medical Center, UPMC Cancer Center, University of Pittsburgh Cancer Institute, Pittsburgh, PA
Saturday, December 3, 2016, 5:30 – 7:30 PM, Hall GH
This poster will review a Phase I clinical trial of the safety and efficacy of "off-the-shelf" aNK cell therapy in heavily pretreated patients with refractory/relapsed AML
CD19 Target Activated Natural Killer (CD19.taNK) Cellular Therapy: A Novel Immunotherapeutic Approach to the Treatment of Non-Hodgkin Lymphoma (NHL)
Abstract #4174, View Source
Presenter: Ravi Dashnamoorthy, PhD, Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA
Monday, December 4, 2016, 6:00 – 8:00PM, Hall GH
This poster will review the potent single agent anti-tumor activity against a range of NHL cell and ongoing activity into the biological mechanisms of activity of CD19.taNK therapy and potential combination therapy approaches.